Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy

Expert Rev Anti Infect Ther. 2012 Jan;10(1):51-61. doi: 10.1586/eri.11.156.


Prevention of cytomegalovirus (CMV) infection is an important part of clinical care provided to patients after solid organ transplantation. While the optimal preventive strategy has not been defined, most centers rely on universal prophylaxis or pre-emptive therapy. This article comments on recent studies designed to identify strategies that effectively reduce the incidence of late-onset CMV disease as the main problem associated with prophylaxis, and on recent data regarding the development of CMV-specific immunity depending on the CMV-preventive regimen used. Despite an apparent trend to prefer prophylaxis in clinical practice, this approach does not seem to be based on robust evidence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acyclovir / analogs & derivatives*
  • Acyclovir / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Clinical Protocols
  • Cytomegalovirus Infections / prevention & control*
  • Ganciclovir / analogs & derivatives*
  • Ganciclovir / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Opportunistic Infections / prevention & control*
  • Organ Transplantation
  • Randomized Controlled Trials as Topic
  • Valacyclovir
  • Valganciclovir
  • Valine / analogs & derivatives*
  • Valine / therapeutic use


  • Antiviral Agents
  • Immunosuppressive Agents
  • Valganciclovir
  • Valine
  • Valacyclovir
  • Ganciclovir
  • Acyclovir